Dendreon: Clinical Trials

5 trials sponsored by Dendreon, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

5 completed. 5 Phase 3.

By phase and status

PhaseTrialsStatus
Phase 35Completed 5

Follow Dendreon: new trials by email

Trials (filtered) newest first · largest first

All 5 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Open- Label Trial of Sipuleucel-T Administered to Active Surveillance Patients for Newly Diagnosed Prostate Cancer
sipuleucel-T - Adenocarcinoma of the Prostate
Phase 3CompletedDendreon5322018-10-182024-10-08
Provenge® (Sipuleucel-T) Active Cellular Immunotherapy Treatment of Metastatic Prostate Cancer After Failing Hormone Therapy
Sipuleucel-T, APC-Placebo - Prostate Cancer
Phase 3CompletedDendreon5122003-07-012010-09-06
PROvenge Treatment and Early Cancer Treatment
Control, Sipuleucel-T - Prostate Cancer
Phase 3CompletedDendreon1762001-10-012018-01-29
Immunotherapy With APC8015 (Sipuleucel-T, Provenge) for Asymptomatic, Metastatic, Hormone-Refractory Prostate Cancer
sipuleucel-T, APC-Placebo - Hormone-Refractory Prostate Cancer
Phase 3CompletedDendreon982000-05-012010-09-08
Vaccine Therapy in Treating Patients With Metastatic Prostate Cancer That Has Not Responded to Hormone Therapy
sipuleucel-T, Placebo - Prostate Cancer
Phase 3CompletedDendreon1271999-11-012010-11-01

Conditions studied

Prostatic Neoplasms (3)  ·  Neoplasms (1)

Interventions

sipuleucel-T (5)

Countries

United States (4)  ·  Canada (1)

Top investigators

Eric J. Small, MD (1)  ·  Nadeem Sheikh, PhD (1)  ·  Paul Schellhammer, MD (1)  ·  Robert Israel, MD (1)

Results publications

PMID 24957547, PMID 35812443, PMID 16809734, PMID 20818862, PMID 23253957, PMID 23896100